The U.S. Food and Drug Administration announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN) on October 22, 2026. The program is designed to advance the science, tools, and regulatory approaches needed to support the development of medical products for conditions affecting the brain and nervous system. NAIN is aligned with the Trump Administration's efforts to accelerate medical innovation and deliver breakthrough treatments.
The inaugural initiative under NAIN is the Alzheimer's Prevention Accelerator. This program will focus on advancing medical products that help delay or prevent Alzheimer's disease. It aims to explore innovative approaches to advancing clinical trials for Alzheimer’s disease prevention and early-intervention drug development. The initiative will emphasize trial populations, stage-appropriate endpoints, and evidentiary approaches for demonstrating prevention or delay of cognitive decline due to Alzheimer’s disease.
NAIN will bring together scientific and regulatory expertise from the FDA's Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health. The program encompasses conditions that affect the brain and nervous system broadly, including neurologic and psychiatric disorders, substance use disorders, and pain. Additionally, NAIN will support robust engagement with patients, industry, academia, and other stakeholders.
Acting FDA Commissioner Kyle Diamantas stated that the launch of NAIN reflects the agency's commitment to ensuring regulatory science and cross-center collaboration keep pace with advances in neuroscience. The program supports the National Alzheimer’s Project Act (NAPA), the federal government's comprehensive roadmap for coordinated action on Alzheimer's and related dementias.
